- Home
- VVV vs RYTM Comparison
VVV vs RYTM Comparison
Compare VVV & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVV
- RYTM
- Stock Information
- Founded
- VVV 1866
- RYTM 2008
- Country
- VVV United States
- RYTM United States
- Employees
- VVV N/A
- RYTM N/A
- Industry
- VVV Major Chemicals
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- VVV Industrials
- RYTM Health Care
- Exchange
- VVV Nasdaq
- RYTM Nasdaq
- Market Cap
- VVV 4.3B
- RYTM 4.3B
- IPO Year
- VVV 2016
- RYTM 2017
- Fundamental
- Price
- VVV $37.88
- RYTM $63.62
- Analyst Decision
- VVV Buy
- RYTM Strong Buy
- Analyst Count
- VVV 12
- RYTM 12
- Target Price
- VVV $42.75
- RYTM $77.50
- AVG Volume (30 Days)
- VVV 2.0M
- RYTM 560.2K
- Earning Date
- VVV 08-06-2025
- RYTM 08-05-2025
- Dividend Yield
- VVV N/A
- RYTM N/A
- EPS Growth
- VVV 56.15
- RYTM N/A
- EPS
- VVV 2.05
- RYTM N/A
- Revenue
- VVV $1,674,400,000.00
- RYTM $136,863,000.00
- Revenue This Year
- VVV $6.67
- RYTM $37.56
- Revenue Next Year
- VVV $15.40
- RYTM $74.99
- P/E Ratio
- VVV $18.57
- RYTM N/A
- Revenue Growth
- VVV 9.56
- RYTM 48.88
- 52 Week Low
- VVV $31.02
- RYTM $40.46
- 52 Week High
- VVV $48.27
- RYTM $69.89
- Technical
- Relative Strength Index (RSI)
- VVV 62.35
- RYTM 46.09
- Support Level
- VVV $36.41
- RYTM $60.70
- Resistance Level
- VVV $37.62
- RYTM $64.00
- Average True Range (ATR)
- VVV 0.87
- RYTM 2.22
- MACD
- VVV 0.10
- RYTM -0.39
- Stochastic Oscillator
- VVV 84.29
- RYTM 8.11
About VVV Valvoline Inc.
Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.